Scientific Poster

Characterization of DS8201 (Enhertu) Clinical Pretreated NSCLC Patient Derived Xenograft Model

Jinxi Wang, Ling Chen, Jun Zhou, Likun Zhang, Wubin Qian, Jian Feng, Leilei Chen, Qingzhi Liu, Binchen Mao, Mingxuan Du, Peng Wang, Ludovic Bourre, Jessie J.J. Wang

HER2 amplification drives a subset of non-small cell lung cancer (NSCLC), yet resistance to HER2-targeted therapies remains a challenge. Crown Bioscience established a clinically derived patient-derived xenograft (PDX) model from a pretreated patient to study DS-8201 (Enhertu) resistance mechanisms and test new therapeutic strategies.

The LU0861 PDX model mimics a real-world clinical history of treatment exposure and disease progression, enabling translational evaluation of resistance biology and combination therapy design.

Download this Poster to Discover:

• How a clinically pretreated NSCLC PDX was developed to model DS-8201 resistance
• In vivo results showing tumor response and mechanisms of acquired resistance
• Characterization of HER2 amplification and molecular alterations in resistant clones
• Insights into combination therapy effects with Tucatinib and DS-8201
• How this model supports more predictive preclinical development in HER2-positive NSCLC

Download the Poster Now!